Navigation Links
Regeneron Announces Appointment of Robert E. Landry as Senior Vice President, Finance and Chief Financial Officer
Date:9/10/2013

TARRYTOWN, N.Y., Sept. 10, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the appointment of Robert E. Landry as Senior Vice President, Finance.  Mr. Landry will also assume the position of Chief Financial Officer of Regeneron on October 1.  After 18 years as CFO, Murray A. Goldberg will transition to a new role as Senior Vice President, Administration in anticipation of his retirement at the end of 2014.

Mr. Landry brings over two decades of varied financial and operating experience in the global pharmaceutical industry, most recently as Senior Vice President and Treasurer of Pfizer, Inc.  He will report to Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  Mr. Landry will have responsibility for all financial functions, including Controller's, Treasury, Financial Planning, Tax, and Internal Audit.  In his new role, Mr. Goldberg will continue to have responsibility for Alliance Management and various administrative functions.

"Murray has been an integral member of the Regeneron senior management team for close to two decades and his contribution to our success as we grew from a development stage biotechnology company to one of the largest biotechnology companies in the world has been invaluable.  We are extremely fortunate that Murray will stay at Regeneron through 2014 to help us with the transition to a new CFO," said Dr. Schleifer.  "Bob Landry brings with him a breadth of domestic and international financial expertise at Pfizer and Wyeth.  We look forward to the valuable perspective he will bring, as we continue to expand our operations in the U.S. and globally."

"I am pleased to be able to join an organization that is known for its deep commitment to science and to bringing life changing medicines to patients," said Robert Landry.  "I am excited about this opportunity and look forward to working with the talented Regeneron management team."

Prior to serving as Senior Vice President and Treasurer of Pfizer, Mr. Landry held a variety of U.S. and international financial and general management positions at Wyeth and Pfizer including Senior Vice President – Finance, Pfizer's Diversified Businesses, Treasurer of Wyeth, Director of Sales and Marketing and Chief Financial Officer for Wyeth Pharmaceuticals' Australian and New Zealand affiliates, and various other assignments in both the pharmaceuticals business and the parent company.  Mr. Landry joined Wyeth after spending two years as an auditor with PricewaterhouseCoopers LLP.  He holds a B.B.A in Accounting from the University of Notre Dame.

About Regeneron Pharmaceuticals
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.  For additional information about the company, please visit www.regeneron.com.Contact Information:Manisha Narasimhan, Ph.D.Peter DworkinInvestor RelationsCorporate Communications914.847.512914.847.764manisha.narasimhan@regeneron.competer.dworkin@regeneron.com


'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regenerons Eylea Now Captures One-Quarter Of Wet AMD Patient Share, Surpassing Share Of Roche/Genentechs Lucentis
2. Quarterly Financial Results and Development Program Updates - Research Report on Regeneron, DaVita, Celldex, Isis, and VIVUS
3. Regeneron Reports Second Quarter 2013 Financial and Operating Results
4. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
5. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
6. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
7. Regeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs
8. Regeneron to Report First Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2013
9. Regeneron Pharmaceuticals Announces Expansion in New Yorks Hudson Valley
10. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
11. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the ... analysis system called the HORIZON at MIBio 2017 in ... subvisible and visible particulate matter in biopharmaceutical samples with unprecedented speed ... of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global ... that its MyDario product is expected to appear on The Dr. Oz ... Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked ... The segment features ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... wound care advancements to physician colleagues, skilled nursing facility medical directors and other ... Treacherous Waters of Wound Care." , "At many of these conferences we get ...
Breaking Medicine News(10 mins):